fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

Fed Minutes Hit Real Estate, Tech & Health Care Stocks Strongly This Week – $CVX $F $DIS $INVO $JPM Rise!

By John F. Heerdink, Jr.
“Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie, Polish Scientist,  November 7, 1867 – July 4, 1934


The Fed came out this week with their ‘Minutes’, which gave the markets a gut check, especially the growth oriented stocks, but also forcing all indices lower. The Fed’s fight against inflation shifted into a higher gear as they threatened to speed up interest rate hikes along with a more rapid removal of liquidity measures, which unfortunately spooked the markets and a rotation of sorts presented its ugly head.  I believe it is safe to say that these guys are not the most clever in handling the narrative these days for those invested in the markets. As a result, the S&P 500 closed at 4,677.03 (-1.9%) for the week with the interest rate dependent real estate sector dropping 4.9% & the information technology & the health care sectors dropping 4.7% equally to lead the decline.  If you were in the energy sector, however,  you were ‘partying like it was 1999’ as it rose an impressive 10.6%. Your smile probably turned south when you approached a gas station as oil prices jumped to close at $79.10/bbl, +5.2% this week pushing gas at the pump higher. Gas prices are now seemingly advancing towards $6/gallon in my hometown of San Francisco. Will someone please put a Tesla in my garage soon? You may be a little happy if you owned Chevron (CVX) as it closed at $125.03, +6.54% over the last 5-days. Moving on, the Dow 30 held up relatively well as it closed at 36,231.66 (-.3%) as the sector rotation into the cyclicals and/or more value oriented issues countered its exposure to tech. The Nasdaq, with a high exposure to tech, had a terrible week as it closed lower at 14,935.90 (-4.5%). The small caps on the Russell 2000 also closed lower at 2,179.81 (-2.9%), while the MicroCaps pulled back as the iShares Micro-Cap ETF (IWC) closed at $136.42, -2.37% over the last 5-days. 

Biotech stocks unfortunately pulled back yet again as the end of tax selling did not prove to improve its situation.  In fact, the biotech sector sold off somewhat indiscriminately as issuers from the top to the bottom of the apple cart moved lower. The Nasdaq Biotechnology ETF (IBB) closed at $140.55, -7.91% over the last 5-days. The NYSE ARCA Biotech Index (^BTK) closed at 5,203.04, -5.72% over the last 5-days. The smaller side of the biotech markets, represented to a degree by the SPDR S&P Biotech ETF (XBI), established a new 52-week low of $102.46 and closed at $102.99, -8.01% over the last 5 days. The XBI’s 52-wk range is $102.46 – $174.79. Hopefully, the annual JPMorgan Biotech and Health Care Conference which is held in San Francisco typically, will unfortunately be held in a virtual format again because of COVID, will still bring forth some increased deal flow, M&A, investment, and speculation over the next week to help pull it out of the cellar. The Health Care Select Sector SPDR (XLV) also moved down this week to close at $134.35, -4.65% over the last 5-days.

The macroeconomic schedule also served up a number of reports this week. On Monday, the total construction spending report showed a .4% M/M rise in November, while the total private construction report showed a .6% M/M rise, & total public construction spending fell by .2%. Now on Y/Y basis the total construction spending was confirmed to be up 9.3%. The preliminary December IHS Markit Manufacturing PMI report confirmed a drop to 57.7. On Tuesday, the December ISM Manufacturing Index report came in +2 points lower at 58.7% vs. the month before, but still well above the Mendoza line and continuing to confirm expansion. It also showed that some prices softened as a supply chain conditions somewhat improved, but the inflation jury is still out. The Job openings report also confirmed a drop to 10.562M in November. We also realized that a record 4.5M individuals were confirmed to have quit their jobs in November and approx. 1.37M people were laid off or fired over the course of the same month. On Wednesday, the ADP report estimated that 807k jobs were added to private sector payrolls in December, the preliminary IHS Markit Services PMI report for December fell to 57.6, the weekly MBA Mortgage Applications Index dropped 5.6%, & the crude oil inventories report confirmed a weekly draw of 2.144M barrels. On Thursday, the Initial claims report for the week ending January 1 rose by 7k to 207k, while the continuing claims report for the week ending December 25 showed a rise by 36k to 1.754M. The ISM Non-Manufacturing Index report for December was confirmed to have dropped to 62% still well above the expansion line. The trade deficit for November moved wide to $80.2B. The Factory orders for manufactured goods report confirmed a rise by 1.6% month/month in November, while shipments of manufactured goods rose .7%. On Friday, December payrolls growth slowed more than expected, while the the labor force participation rate held steady at 61.9% & average hourly earnings cam in better than expected at .6%. The Consumer credit report showed a rise by $39.9B in November.

The yield curve edged higher this week with the 10-yr yield up 16 basis points to close at 1.77% and the 2-yr yield closed at .87%, up 14 basis points.

The U.S. Dollar Index edged higher this week to end at 95.75 moving up from the 95.63 mark last week.



EV, TECH, CONSUMER, FINANCIALS

Apple (AAPL) closed at $172.17, -3.04% over the last 5-days, but after surged in the early part of the week & became the first company on the planet to have ever reached a $3T market cap!

EV giant Tesla (TSLA) moved lower to close at $1026.96, -2.82% over the last 5-days. On January 2, Tesla reported that they achieved production of more than 305,000 vehicles and deliveries of over 308,000 vehicles in Q4 & that in 2021, they delivered over 936,000 vehicles, thus beating expectations. A Wedbush sell side analyst Dan Ives stated recently that he thinks Tesla shares could be headed to $1,800.

Shares of Ford (F) closed at $24.44 up a whopping +17.67% over the last 5-days. This week, Ford confirmed that it was the Best-Selling Automaker in Q4, it achieved a No. 2 rank for Electric Vehicle Sales for 2021, the F-Series is the Best-Selling Truck for 45th Year In Row and Best-Selling Vehicle for 40th Straight Year, while their SUV Share Expands. 

Shares of JPMorgan (JPM) closed at $167.16, +5.56% over the last 5-days alone with the financial sector was up 5.4% this week as interest rates rose.  JPMorgan Chase & Co will host a conference call to review fourth-quarter and full-year 2021 financial results on Friday, January 14, 2022 at 8:30 a.m. (EST). The results are scheduled to be released at approximately 7:00 a.m. (EST). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations.




Amazon.com, Inc. (NASDAQ: AMZN, $3,251.08, -2.5% over the last 5-days. On Jan. 5, Amazon and Stellantis N.V. (NYSE/MTA/Euronext Paris: STLA), a leading global automaker and mobility provider, announced a series of global, multi-year agreements that will transform the in-vehicle experience for millions of Stellantis customers and advance the mobility industry’s transition to a sustainable, software-defined future. Stellantis will accelerate its shift to becoming a sustainable mobility tech company through this relationship, which involves Amazon Devices, Amazon Web Services (AWS), and Amazon Last Mile. Stellantis and Amazon will collaborate to deploy Amazon’s technology and software expertise across Stellantis’ organization, including vehicle development, building connected in-vehicle experiences, and training the next generation of automotive software engineers. Together, the two companies will create a suite of software-based products and services that seamlessly integrate with customers’ digital lives and add value over time through regular over-the-air (OTA) software updates.

Shares of Microsoft Corp. (MSFT) closed at 314.04, -6.62% over the last 5-days. This spring, OPI is teaming up with Xbox to launch a vibrant collection of 12 winning hues. Available in four different formulas with colors ranging from fresh blues and greens to fantastical shimmers, this palette brings the virtual worlds of gaming to life so you can unlock endless looks and play with nail art and new trends.

NVIDIA (NVDA) closed $272,47, -7.36% over the past 5-days. This week at CES, NVIDIA announced that they set out the next direction of the ultimate platform for gamers and creators, unveiling more than 160 gaming and Studio GeForce®-based laptop designs, as well as new desktop and laptop GeForce RTX® GPUs and technologies. The company also announced new RTX-accelerated content, and the expansion of both GeForce NOW™ cloud gaming and the NVIDIA Studio ecosystem, including the launch of NVIDIA Omniverse™ for creators.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $84.42, -10.75% over the last 5-days. 

The Technology Select Sector SPDR Fund (XLK) closed at $165.93, -4.57% over the last 5-days.

Disney (DIS) closed at $157.83, +1.90% over the last 5-days. Recently, former Walt Disney CEO Bob Iger reportedly stated that in order to hit lofty subscriber goals, Disney+ needs “more content for more people.” Disney also reiterated its goal of reaching 230 million to 260 million Disney+ subscribers by 2024 during its fiscal fourth-quarter earnings report in November. At that time, the company said it had a total of 118.1 million subscribers. The annual meeting of shareholders of The Walt Disney Company (NYSE: DIS) will be held on Wednesday, March 9, 2022 at 1:00 p.m. ET / 10:00 a.m. PT by virtual meeting and will be made available via webcast at www.disney.com/investors.

Shares of McDonald’s (MCD) closed at $267.06, -.38% over the last 5-days. 

GOLD & SILVER

Gold prices closed back below $1800 at $1,797, -$19 for the week & silver prices closed at $22.37, -$.73/oz. for the week. Hecla Mining (HL) closed at $4.867, -6.97% over the last 5-days. First Majestic (AG) closed at $10.32, -7.11% over the last 5-days.


MEMES REPORT

AMC Entertainment (AMC) closed at $22.00, -15.48% over the last 5-days. 

GameStop (GME) closed at $140.62, -5.24% over the last 5-days.  

Bed Bath & Beyond Inc. (NASDAQ: BBBY) shares closed at $13.80, -5.35% over the past 5-days. BBY reported its Q3 results missing expectations with net sales at $1.297 billion for the quarter, compared to $1.005 billion in the prior year’s third quarter & sales attributable to new and expanded brand relationships, such as Samsung, LG, Razer, Vizio and others, contributed to the Company’s growth in the quarter.

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $.936, +1.74% over the last 5-days. On Dec. 16, Seanergy announced that it has entered into a definitive agreement for the refinancing of a loan facility secured by M/V Geniuship, with a new loan facility secured by the same vessel. The significantly lower interest rate, as well as the reduced quarterly repayments agreed for 2023 onwards, will further improve the break-even rates of the underlying vessel. In addition, the interest savings for the Company are expected to be $0.9 million for 2022 and $0.5 million on average per year for 2023-25.

BITCOIN

Bitcoin $BTC.X closed at $41,532.44, -10.65% over the last 5-days.

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $55.50, +1.09% over the last 5-days & +46.44% YTD. Oil prices closed at $75.50/bbl up 2.3% for the week & us now up 55.6% for the year. 

NEXT WEEK

The stock market will be back to a normal 5-day trading week next week as there will be no observance or time off to recognize the New Year’s Holiday. 

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


  • Shares of INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $8.99, -11.86 over the last 5-days. The 52-wk range is $8.72 – $30.37.
    • On Dec. 9, INMB announced data to be presented at the San Antonio Breast Cancer Symposium showing mucin 4 (MUC4) expression predicts worse survival and is a treatment resistance factor in women with triple negative breast cancer (TNBC). INB03, a DN-TNF therapy, can reverse TNBC treatment resistance by decreasing expression of MUC4 and reducing immunosuppression in the tumor microenvironment (TME) by increasing anti-tumor macrophage phagocytosis and increasing lymphocyte function in the TME. The poster will be presented by Dr. Roxana Schillaci, Instituto de Biología y Medicina Experimental, Buenos Aires, on December 10th. RJ. Tesi, M.D, Chief Executive Officer of INmune Bio, commented, “We are excited to have Dr. Schillaci present these data that expand on her previous findings on the role of MUC4 expression which predicts worse survival and resistance to therapy in HER2+ breast cancer therapy. Now, in both TNBC and HER2+ breast cancer, MUC4 predicts resistance to immunotherapy and an immunosuppressive TME that can be overcome with INB03.” Treatment with INB03 in murine models of breast cancer improves macrophage anti-tumor phagocytic activity, lymphocyte infiltration and function suggesting improved response to combination therapies of INB03 with inmunotherapy.
    • On Dec. 1,  INmune Bio announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK. Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, stated, “I’m delighted to have two of our team presenting our latest data on the mechanism of action of INKmune. These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK). Before this, mlNK cells could only be produced using multiple combinations of cytokines. These are the data which led us to the concept that INKmune is a ‘pseudokine’ that provides multiple signals to NK cells, akin to the multi-cytokine cocktails used by others. We also show that INKmune priming promotes significant proliferation of mlNK cells in vitro. These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS. At 119 days post first treatment, 60% of the patient’s NK cells showed the activated, tumor killing phenotype compared to fewer than 15% before INKmune therapy. The patient remains well and with a significantly improved ECOG status.”

    • Recently, INMB presented multiple poster presentations and a plenary talk at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that was held from November 9-12 in Boston. Learn more. 
    • The Maxim Group’s analyst Jason McCarthy confirmed his $42 Price target recently.  
    • On Nov. 3rd, INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” INmune Bio announced that they will deliver multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that is being held during November 9-12 in Boston. For details please visit the following link. 
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has been viewed over +30k times now to learn more.
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.



  • Shares of InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed at $1.28, -2.29% over the last 5-days. Please visit the INM page at our website to learn more and check out the videos section too. The 52-wk range is $1.2545 – $8.94. 
    • This week our sister organization,  Tribe Public, held a FREE Webinar Presentation and Q&A Event with InMed Pharmaceuticals (NASDAQ: INM) titled “Addressing The Increasing Demand For Rare Cannabinoids” with Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) SVP, General Manager of BayMedica Shane Johnson, MD & VP, Commercial Operations Chris Meiering, PhD. The event was very interesting and informative, well attended, and now the event video is now published at the Tribe Public YouTube Channel. You may view it now by clicking here

    • On Dec. 20, InMed announced that a peer-reviewed scientific article entitled “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma”, has been published in Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease), a leading international journal focused on biochemistry and molecular genetics of disease processes and models of human disease in the area of aging, cancer, metabolic-, neurological-, and immunological-based diseases. The peer-reviewed article highlights research evaluating the use of cannabinol, or CBN, as a potential treatment option for glaucoma. Several studies were conducted to evaluate the survival of retinal ganglion cells, modulation of intraocular pressure and its effects on extracellular matrix proteins using in vitro and in vivo glaucoma models. These studies resulted in two key findings: first, CBN may promote neuroprotection of cells in the retina that are responsible for vision; and second, CBN may normalize intraocular pressure by attenuating changes in the extracellular matrix proteins. The article also reports on the comparison of CBN with other cannabinoids, including cannabidiol (CBD) and tetrahydrocannabinol (THC), with results indicating that CBN has a stronger effect and broader neuroprotective therapeutic range. These observations elucidate the therapeutic potential for CBN in the treatment of glaucoma.
    • On Nov. 29, InMed Pharmaceuticals (NASDAQ: INM) received a BUY Recommendation from Raghuram Selvaraju, Ph.D. a sell side analyst at H.C. Wainwright & CO. with a Price Target of $6. His report is titled “Charging After Pharmaceutical-Grade Cannabinoids; Initiating at Buy and $6 PT”.  
    • On November 10, InMed announced their financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $48.31, -17.43% over the last 5-days. 
    • On Monday, Dec. 13, Fate showcased positive interim Phase 1 data from the Company’s FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. FT596 is the Company’s off-the-shelf, multi-antigen targeted, iPSC-derived natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. “The interim dose-escalation clinical data from our FT596 program in relapsed / refractory B-cell lymphoma demonstrate that off-the-shelf, iPSC-derived CAR NK cells can bring substantial therapeutic benefit to heavily pre-treated patients in urgent need of therapy, with high response rates and meaningful duration of responses,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We are particularly pleased with the therapeutic profile that has emerged with FT596 in combination with rituximab, where over half of the patients treated with a single dose of FT596 at higher dose levels achieved a complete response with a favorable safety profile that is clearly differentiated from CAR T-cell therapy. We look forward to assessing a two-dose treatment schedule for FT596 to further define its potential best-in-class therapeutic profile and ability to reach more patients, including those earlier in care.”

    • On Nov 4, FATE reported business highlights and financial results for the third quarter ended September 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December. We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted, CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $1.53, -4.83% over the last 5-days. 
    • On Dec. 22, Atossa announced that it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden. Participants in the study will be premenopausal women with elevated mammographic breast density, which is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. “This is an extremely important milestone as it marks the next phase of developing our proprietary Z-Endoxifen,” said Steven Quay, M.D., Ph.D., Atossa’s Chairman and CEO. “This study will help determine the relationship between daily doses of Endoxifen and reduction in breast density and will help us further assess safety and tolerability. We look forward to providing progress updates as they become available.” Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, recently published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • Recently, Physician-Scientist and CEO of Atossa, Steven Quay, MD, PhD, published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in September 2021. At the time, BANAL-236 was the first bat coronavirus with high homology to SARS-CoV-2 that could directly infect human cells using the same receptor that SARS-CoV-2 uses. The new research reports that BANAL-236 has evolved the ability to infect human cells by an unknown mechanism that violates over 40 years of coronavirus research. The COVID-19 e-print is available here and has also been submitted to Nature. “When I read the paper from the Institut Pasteur and looked at the virus, I immediately assumed there was an error in either the way the sequence was assembled or a mix up in the lab with another virus to explain the infectivity,” Quay said. “I contacted the Institut Pasteur with my findings and was deeply disturbed to learn that there was not, in fact, some simple mistake had occurred to explain things. I now knew we were in uncharted waters with a virus that is missing eight key elements that have been shown, over 40 years of research, to be required for growth.”
    • On Dec. 6, Atossa announced that it has completed a pre-investigational new drug (PIND) meeting with the FDA. The purpose of the meeting was to obtain input from the FDA on pre-clinical, clinical, manufacturing and regulatory matters in the U.S. for Atossa’s proprietary Z-endoxifen to treat breast cancer in the neoadjuvant (prior to surgery) setting. “Holding a PIND meeting is a critical milestone in the regulatory pathway,” said Dr. Heather Fraser, Atossa’s VP Clinical, Regulatory and CMC. “The feedback we received will be very helpful in preparing our request to the FDA to open an IND for a multi-center Phase 2 study to further advance our Z-endoxifen in the neoadjuvant setting. We plan to focus our development on pre-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer for whom the current treatment options typically include drugs that suppress ovarian function and essentially force the patient into menopause. We look forward to opening an IND in the second quarter of 2022 and then commencing a Phase 2 study in this setting. Despite the uncertainties and challenges created by the worldwide, COVID-19 pandemic in 2021, it is gratifying to be able to announce this major step forward for our proprietary Z-endoxifen program development in the U.S., the largest market for pharmaceuticals for the treatment of breast cancer,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “The guidance from this meeting with the FDA, together with the ongoing non-clinical studies with Z-endoxifen and the initiation of a technology transfer process to establish a commercial cGMP manufacturing supplier to support the further drug development and ultimate commercial launch of Z-endoxifen, will put Atossa in an excellent position to continue the development of Z-endoxifen in 2022.”
      Based in part on the feedback received from the FDA and subject to its approval, Atossa’s current plan, is to continue developing Z-endoxifen for the treatment of pre-menopausal women with ER+/HER2- breast cancer in the neoadjuvant setting. Atossa plans to apply to the FDA for an IND to conduct a Phase 2 study in the U.S. to compare Z-endoxifen to standard of care, which is typically ovarian functional suppression along with either an aromatase inhibitor or tamoxifen. Atossa also plans to conduct a pharmacokinetic run-in study as a part of the Phase 2 study to further define potential dose levels.

    • On Nov. 30,  Atossa Therapeutics’ CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO presented at our sister organization Tribe Public’s FREE Webinar Presentation and Q&A Event. During this complimentary event, Atossa management addressed Q&A from the Tribe focused on Atossa’s research programs and future development. You can watch the event video titled “A Town Hall Q&A Event With Atossa Therapeutics Management Team” at the Tribe Public YouTube Channel by clicking here
    • On Nov. 15, Atossa announced their financial results for the fiscal quarter ended September 30, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “Our progress in both the Endoxifen and COVID-19 programs, with our initiation of our trial in Australia for AT-H201, and our receipt of regulatory authorization in Sweden to commence an Endoxifen Phase 2 trial, have been key recent milestones, positioning us to move both of these programs forward and take the next steps toward developing therapies in urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value,” Review the balance of the story here. 
    • On October 23, Dr. Steven Quay CEO of Atossa Therapeutics (NASDAQ: ATOS) published an interesting and informative video called “Long COVID Is An important Issue.” You may view by clicking here now.
    • On September 30, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  •  

  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.49, +4.80%, & has traded up to $3.7, +6.02% in the aftermarket on Friday.   
    • On Dec, 16, , INVO Bioscience, Inc. announced that it has entered into an expanded agreement with Ovoclinic, a group of clinics specialized in assisted reproductive treatments with four locations across Spain (Madrid, Marbella, Málaga, Ceuta) and collaborating centers around Europe, to accelerate adoption of INVOcell within their markets. The agreement includes the expanded adoption of INVOcell within Ovoclinic locations as well as establishing an INVO Center of Excellence for future training for the European Market. Cristina Gonzalez, embryologist and Quality Manager of Ovoclinic laboratories stated, “After several successful trials implementing the exciting INVOcell fertility treatment, Ovoclinic aims to provide its patients with this effective alternative to the processes used so far in Spain in the field of reproductive medicine. We consider INVOcell to be an effective method of natural reproduction that involves the future mother at the very first moment of the process. We are confident that this innovative treatment will help many patients to choose this new alternative solution to achieve their dream of forming a family by actively participating in the reproductive process.” According to the World Bank, Spain, with total population of approximately 47 million people, has one of the lowest fertility rates in Europe, affecting approximately 15% of the population, or one in seven couples of reproductive ages. According to reports, in 2010, there were approximately one million couples requesting assisted reproductive treatment, however only 22% received one or more assisted reproductive treatment cycles. The average waiting time for an IUI or IVF cycle in a public health facility was 339 days. Ovoclinic reports that they maintain the best technical and human resources to deal with all kinds of infertility problems along with the simplest and most natural treatments to the most complex and advanced techniques pioneered in Spain. Ovoclinic also works in partnership with Ovobank, the first European Donor Egg Bank in Europe.
    • On Dec. 1, INVO Bioscience announced the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand. In April 2021, INVO Bioscience entered an exclusive distribution agreement with IVF Envimed Company Ltd. to distribute the INVOcell system within Thailand. Established in 1993, IVF Envimed Company Ltd. has established a wide network of clinics and hospitals across Thailand primarily focused on fertility solutions. IVF Envimed is a member of the ‘Thai Society of Reproductive Medicine’ which organizes congresses and educational programs where IVF Envimed participates. In November 2021, INVO Bioscience started to train physicians and embryologists from both private and government hospitals. In early 2022, INVO Bioscience and IVF Envimed will organize several ‘in person’ trainings in Bangkok with key fertility experts to supplement currently ongoing online trainings. INVO Bioscience is also planning to conduct a locally-based evaluation study to have localized data, a key element for both physicians and patients. “Following months of efforts and interactions with the governmental authorities in Thailand, we are thrilled to have received approval by FDA Thailand to commence commercialization of the INVOcell solution within Thailand,” commented, Steve Shum, CEO of INVO Bioscience. “Over the past number of months, we have been working closely with our partners at IVF Envimed to educate key opinion leaders within the country, including the recent training of several physicians and embryologists that should allow us to begin scaling up our commercialization efforts within the country. Further, we have identified physicians to help us with localized data collection on initial patients to assist in our longer term marketing efforts within the country. We look forward to working with Envimed and supporting their efforts to deliver the INVOcell solution in Thailand help address the underserved patient market in need of advanced reproductive treatment.”
    • On Nov 16, Colliers Secuirites issued an update report titled “Dedicated INVOcell Clinics To Begin Meaningful Sales in CY22. Decision On 5-Day label Expansion Expected in 1Q22.” The report carried a BUY rating on INVO and a Price Target of $6.
    • On Nov. 15, INVO announced their financial and operating results for the third quarter ended September 30, 2021, and provided a business update. Steve Shum CEO of INVO stated , “We continue to execute against our core mission of improving access to advanced fertility services for the many patients around the world through the use of the INVOcell solution. During the quarter, we achieved a significant milestone with the opening of our very first INVO Center, based in Birmingham, where we have commenced initial cycles. Further, we opened clinics in Atlanta, Georgia and Monterrey, Mexico to expand the INVO Center business model and we are working to open the San Francisco Bay Area clinic as soon as possible. We completed the acquisition of a Canadian-based entity that will be used to distribute the INVOcell in Canada and to develop INVO Centers in the region. With our INVO Center strategy now successfully underway, we are optimistic on the prospects for further expansion using this unique and innovative model. As part of a detailed review, we have initially identified more than 20 cities here in the U.S. that we believe have excellent characteristics in terms of demographics and level of current fertility care that would be ideal locations for an INVO Center.” READ the balance of the story here. 
    • On Nov. 8 after the market closed, INVO announced that it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.’s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022. Over the past three years, INVO has been executing on a multi-faceted commercialization strategy which includes partnering to open dedicated “INVO Centers” focused on INVOcell and the IVC procedure, and establishing agreements with distributors in key markets. The terms of the U.S. Distribution Agreement had limited the number of INVO Centers that we were allowed to operate. INVO can now further support U.S. fertility clinicians directly as the exclusive provider of INVOcell® in pursuit of our mission to bring advanced fertility care to the millions of people that are without access to treatment.
    • On October 20, INVO Bioscience, Inc. announced that four exciting poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland. “It’s extremely rewarding to see our technology highlighted at this year’s ASRM. Four independent abstracts were selected for presentation at the fertility industry’s most prominent annual meeting. On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,” stated Steve Shum, CEO of INVO Bioscience. LEARN MORE! 
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
      • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
      • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

INVO

    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.
    • On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.



  • Shares of NeuBase Therapeutics (NASDAQ: NBSE),  a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, closed at $2.58, but has traded up to $2.86, +10.86% in the aftermarket on Friday.
    • On Jan. 5, Neubase announced the appointment of Eric J. Ende, M.D., to the Company’s Board of Directors. Dr. Ende has nearly 25 years of experience in advising biotechnology and life sciences companies to optimize corporate strategy and structure and maximize shareholder value. “Dr. Ende has the experience and perspective to recognize the opportunity ahead for NeuBase as it plans for the clinical development of its potentially transformational new class of precision genetic medicines,” said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. “We welcome Dr. Ende’s strategic insight as we begin to scale our therapeutic candidate pipeline from our new precision genetic medicines platform technology. In addition to his broad experience, he also shares in our Company’s goal of helping millions of patients with both common and rare conditions that currently have limited or no treatment options.” “I believe NeuBase has a game-changing technology that overcomes the limitations of early precision genetic medicines by delivering mutation selectivity, repeat dosing, and systemic administration in a modular precision medicine platform with the potential to efficiently scale to treat a wide variety of diseases that are currently undruggable,” said Dr. Ende. “I look forward to working closely with NeuBase’s leadership team and Board of Directors to elevate strategy and operations in order to create exceptional value for patients and shareholders.” Dr. Ende currently is the President of Ende BioMedical Consulting Group. He also is a member of the Board of Directors of Matinas BioPharma, where he is the Chairman of the Compensation Committee and serves on the Audit and the Nomination & Governance Committees, and of Avadel plc, where he is the Chairman of the Nomination & Corporate Governance Committee and serves on the Audit and Compensation Committees. Dr. Ende previously served on the Board of Directors of Progenics (acquired by Lantheus Holdings) and Genzyme (acquired by Sanofi-Aventis for $20 billion). During his time on Genzyme’s Board of Directors, Dr. Ende was a member of the Audit and Risk Management Committees. Prior to Genzyme, Dr. Ende was a biotechnology analyst, previously serving at Merrill Lynch, BofA Securities, and Lehman Brothers. Dr. Ende received an M.B.A. from NYU Stern School of Business, an M.D. from the Icahn School of Medicine at Mount Sinai, and a B.S. in biology and psychology from Emory University.
    • On Dec. 23, NeuBase reported its financial results for the fiscal year ended September 30, 2021, and other recent developments. As of September 30, 2021, the Company had cash and cash equivalents of approximately $52.9 million, compared with approximately $32.0 million as of September 30, 2020. NeuBase estimates its current cash and cash equivalents are sufficient to fund currently planned operating and capital expenditures into the first quarter of CY2023.
      • “NeuBase is focused on significantly reducing the burden of untreatable morbidity and mortality caused by rare and common diseases across the globe. To achieve this goal, we designed, built, and validated a new precision genetic medicines platform technology that can uniquely drug the double-stranded human genome and address disease at the root of causality without many of the limitations of early precision genetic medicine technologies. We are poised to file our first Investigational New Drug (‘IND’) applications with the U.S. Food and Drug Administration (‘FDA’) beginning in calendar year 2022 and intend to scale into additional indications with increasing speed and efficiency thereafter,” said Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase.
      • “This past year, we validated the ability of our technology in proof-of-concept studies to directly drug the double-helix of the human genome, including difficult double-stranded structures of RNA targets, and engage with mutant genes to resolve most causal mechanisms of disease. The validation of our platform’s capabilities included data describing that we have overcome many limitations of early precision genetic medicine technologies, such as biodistribution, tolerability, selectivity, manufacturability, durability, and scalability. We also presented data that our delivery shuttle enables compounds to elicit pharmacologic effects in multiple tissues, including in the brain and muscle, after subcutaneous administration in preclinical animal models,” said William Mann, Ph.D., M.B.A., Chief Operating Officer of NeuBase.
      • “We recently nominated the development candidate for our myotonic dystrophy type 1 (DM1) program, which we believe has the potential to be a best-in-class therapy that offers a patient-friendly route of administration, a whole-body solution for the muscle, heart, and brain manifestations of the disease. Furthermore, the mechanism of action of our development candidate is designed to engage with the toxic RNA hairpin structure to release the splicing proteins, restoring normal RNA splicing and downstream protein production, including DMPK. We have initiated IND-enabling studies for this candidate, with data read-outs expected across CY2022. We expect these data will support the submission of an IND filing to the FDA in the fourth quarter of CY2022,” stated Sandra Rojas-Caro, M.D., Chief Medical Officer of NeuBase.
      • “As a result of the nomination of our DM1 program candidate, we established CMC expertise at our new facility in Cambridge, Massachusetts that is co-located with our clinical development team, finalized the formulation of our development candidate to enable systemic routes, and completed process development. We also scaled-up manufacturing in-house and with contract manufacturing partners to support non-clinical toxicology, product stability, and Phase 1/2 clinical trials,” said Tony Rossomando, Ph.D., Chief Technology Officer of NeuBase.
      • Dr. Stephan concluded, “In parallel, we are making significant progress in our therapeutic program for Huntington’s disease. For example, we have illustrated with preclinical in vivo data that our proprietary delivery technology allows our genome-targeting compounds to advance beyond intrathecal delivery and enabling a systemically administered allele-selective therapy, overcoming challenges seen with other programs. Furthermore, preclinical data show that our PATrOL™-enabled compounds can silence activating KRAS point mutations in vivo to inhibit protein production, which has the potential to target G12D and G12V, the two most common and historically ‘undruggable’ cancer-driving point mutations that represent the majority of KRAS tumors. We believe these data set the stage for a potentially first-in-class precision genetic medicine approach for oncology capable of selectively targeting mutations at the single-base level.”

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  2. There is little that can withstand a man who can conquer himself.” – Louis XIV
  3. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  4. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  5. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  6. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius
  7. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  8. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  9. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  10. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  11. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  12. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  13. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  14. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  15. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  16. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  17. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
  18. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  19. “The secret of getting ahead is getting started.” – Mark Twain
  20. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe
  21. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  22. “If a man does not keep pace with his companions, perhaps it is because he hears a different drummer. Let him step to the music which he hears, however measured or far away.” – Henry David Thoreau
  23. “Adopting the right attitude can convert a negative stress into a positive one.” – Hans Selye
  24. “Money is something that keeps you alive and healthy and just keeps you focused. It’s the drive. It’s the passion.” – Travis Scott
  25. “Common sense is the collection of prejudices acquired by age eighteen.” – Albert Einstein
  26. “Live life to the fullest, and focus on the positive.” – Matt Cameron
  27. “You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln
  28. “However difficult life may seem, there is always something you can do and succeed at.”– Stephen Hawking
  29. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
  30. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  31. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  32. Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  33. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  34. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  35. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  36. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  37. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  38. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  39. “If opportunity doesn’t knock, build a door.” – Milton Berle
  40. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  41. “The smallest deed is better than the greatest intention.” – John Burroughs
  42. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  43. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  44. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  45. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  46. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  47. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  48. “Don’t go through life, grow through life.”– Eric Butterworth
  49. “This life is worth living, we can say, since it is what we make it.” – William James
  50. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  51. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  52. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  53. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  54. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  55. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  56. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  57. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  58. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  59. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  60. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  61. “One fails forward toward success.” – Charles Kettering
  62. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  63. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  64. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  65. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  66. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  67. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  68. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  69. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  70. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  71. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  72. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  73. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  74. “It takes a long time to grow an old friend.” – John Leonard
  75. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  76. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  77. “Man is only great when he acts from passion.” – Benjamin Disraeli
  78. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  79. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  80. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  81. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  82. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  83. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  84. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  85. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  86. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  87. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  88. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  89. “Every good painter paints what he is.” – Jackson Pollock
  90. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  91. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  92. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  93. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  94. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  95. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  96. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  97. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  98. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  99. “Eliminate emotion from your investment program.” -John C. Bogle

  100. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  101. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  102. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  103. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  104. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  105. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  106. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  107. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  108. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  109. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  110.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  111. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  112. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  113. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  114. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  115. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  116. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  117. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  118. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  119. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  120. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  121. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  122. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  123. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  124. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  125. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  126. “View health as an investment, not an expense.” – John Quelch

  127. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  128. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  129. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  130. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  131. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  132. “A problem is a chance for you to do your best.”–  Duke Ellington
  133. “The best way to predict the future is to create it.” -Peter Drucker
  134. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  135. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  136. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  137. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  138. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  139. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  140. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  141. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  142. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  143. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  144. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  145. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  146. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  147. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  148. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  149. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  150. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  151. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  152. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  153. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  154. “Modern medical advances have helped millions of people live longer, healthier lives.

  155. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  156. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  157. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  158. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  159. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  160. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  161. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  162. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  163. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  164. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  165. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  166. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  167. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  168. “Investment is most successful when it is most businesslike.” – Ben Graham

  169. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  170. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  171. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  172. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  173. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  174. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  175. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  176. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  177. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  178. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  179. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  180. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  181. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  182. “Know what you own, and know why you own it.” – Peter Lynch
  183. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  184. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  185. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  186. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  187. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  188. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  189. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  190. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  191. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  192. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  193. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  194. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  195. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  196. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  197. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  198. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  199. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  200. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  201. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  202. “No Price is too low for a bear or too high for a bull.” — Anonymous
  203. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  204. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  205. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  206. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  207. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  208. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  209. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  210. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  211. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  212. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  213. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  214. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  215. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  216. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  217. “Know what you own, and know why you own it.” – Peter Lynch
  218. “Liquidity is only there when you don’t need it.” -Old Proverb
  219. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  220. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  221. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  222. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  223. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  224. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  225. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  226. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  227. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  228. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  229. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  230. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  231. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  232. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  233. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  234. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  235. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  236. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  237. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  238. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  239. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  240. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: